Traws Pharma Enters Stock Purchase Agreement With Roth Principal Investments On Oct 23, 2026; May Sell Up To $50M In Common Stock To Roth Principal Investments
-SEC Filing
Share
Why It Matters
Traws Pharma agreed to possibly sell up to $50 million in company shares. This gives the company money to use, so watch if they need cash badly.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.